
    
      This is a single arm, open-label, single-center study. This study is indicated for relapsed
      or refractory BCMA/TACI positive relapsed and/or refractory multiple myeloma. The selections
      of dose levels and the number of subjects are based on clinical trials of similar foreign
      products. 36 patients will be enrolled. Primary objective is to explore the safety, main
      consideration is dose-related safety.
    
  